Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02151825
Other study ID # 2011F7611
Secondary ID 110021
Status Completed
Phase N/A
First received May 28, 2014
Last updated May 28, 2014
Start date September 2011
Est. completion date October 2012

Study information

Verified date May 2014
Source Texas State University, San Marcos
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effects of a synbiotic (ProSynbiotic) on the gut microbiota composition, body composition and adiposity-related genes and metabolic markers in healthy overweight adult subjects.


Description:

This is a parallel, double-blind, randomized, placebo controlled trial to determine the effects of a synbiotic formulation (ProSynbiotic) containing 4 billion CFU of a probiotic blend of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii, along with 1 g of the prebiotic inulin and 100 mg of galactooligosaccharide (GOS) on the gut microbiota composition, body composition, expression of genes mediating dietary energy harvest and adiposity, and on adiposity-related metabolic markers in healthy free-living overweight or moderately obese subjects. The duration of the study is 18 weeks, including a 2-week run-in period before randomization of subjects into the synbiotic or placebo group, a 12-week intervention period, and a 4-week follow-up after the end of the intervention. During the intervention period, subjects will be instructed to take 3 capsules of either synbiotic or placebo per day and maintain their habitual diet and physical activity. They will also be asked to document any unusual symptoms or side effects as well as keep a bowel diary. Diet and physical activity will be monitored via 24-h dietary recalls and the global physical activity questionnaire respectively. Changes in the gut microbiota composition will be determined by measuring bacterial population levels in stool sampled collected at baseline, 6 weeks, 12 weeks and the follow up time point. Body composition will be measured using the BOD POD at baseline, 6 weeks, and 12 weeks. Gene expression levels will be assessed at baseline and 12 weeks in colonocytes (isolated from stool samples) and PBMCs (isolated from blood samples) by qPCR. Metabolic markers will be measured at baseline and 12-weeks in plasma or serum using the respective biochemical- or immuno-assays.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date October 2012
Est. primary completion date September 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria:

- Age between 18-64

- BMI of 25-34.9 and/or a waist circumference >35 inches for women and >40 inches for men

- Generally healthy except for overweight or moderately obese

- A signed consent form

- Passed a screening questionnaire and willingness to comply with study procedures

- Lipid levels, fasting glucose, liver function and complete blood counts within the normal reference ranges as measured in a screening blood sample

Exclusion Criteria:

- Persons on a weight-loss regimen

- Antibiotic use (< 3 months before the study)

- Regular probiotic, prebiotic or synbiotic use (< 1 month before the study)

- Regular use of anti-inflammatory drugs, weight-loss medications or supplements (< 1 month prior to the study)

- Personal history of cardiovascular disease, hypertension, cancer, type 1 or type 2 diabetes and inflammatory gastrointestinal disorders such as Crohn's disease or colitis

- Smoking

- Consumption of >2 units of alcohol per day

- Pregnancy or lactation

- Irregular periods, menopause or hormone replacement therapy

- Over 300 minutes of exercise per week

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Synbiotic
3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
Other:
Placebo
3 capsules of Maltodextrin per day

Locations

Country Name City State
United States Texas State University San Marcos Texas

Sponsors (2)

Lead Sponsor Collaborator
Texas State University, San Marcos Standard Process Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes to the gut microbiota The primary objective of this study is to determine the effect of a synbiotic formulation called ProSynbiotic (administered at 3 capsules/day) containing 4 billion CFU of a probiotic blend of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii, along with 1 g of the prebiotic inulin and 100 mg of galactooligosaccharide (GOS) on the gut microbiota of healthy overweight adult subjects when compared to a placebo of maltodextrin. Changes in the gut microbiota will be determined by measuring specific bacterial population levels in the subjects' fecal samples, using 16S rRNA targeted oligonucleotide probes and fluorescence in situ hybridisation. 0-weeks (Baseline), 6-weeks (midpoint of intervention), 12-weeks (end of intervention) and 16-weeks (4-weeks after end of intervention) No
Secondary Body composition The effect of Prosynbiotic on the subjects' body composition will be evaluated by BOD POD assessment carried out at baseline, 6-weeks and 12-weeks. Baseline, 6-weeks and 12-weeks. No
Secondary Expression of genes mediating dietary energy harvest and adiposity This will be achieved by measuring the gene expression levels of ANGPTL4, PPAR-? and GPR41/43 in colonocytes isolated from stool and that of ANGPTL4, PPAR-?, NF-kB, IL-6 and TNF-a in PBMCs isolated from blood collected from the subjects at baseline and 12-weeks. Baseline and 12-weeks No
Secondary Adiposity-related metabolic markers This will be achieved by measuring TNF-a, adiponectin, total cholesterol, LDL-C, HDL-C, triglycerides and glucose levels in fasting blood samples collected from the study subjects at baseline and 12-weeks. Baseline and 12-weeks No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04991792 - Effect of an Infant Formula With Synbiotics in Infants Born Via Caesarean Section N/A
Completed NCT01545219 - A Study of a Prebiotic, a Probiotic and a Synbiotic Upon the Gut Microbiota and Immune Response of Healthy Volunteers N/A
Active, not recruiting NCT04435548 - Westlake Gut Microbiome Study
Enrolling by invitation NCT05057039 - The Study of Gut Microbiota in Hypertensive Patients
Not yet recruiting NCT05039060 - Modified MAC Diet and Gut Microbiota in CRC Patients N/A
Completed NCT03746158 - Interindividual Variation in Excretion of Curcumin N/A
Active, not recruiting NCT03266055 - Effects of Blueberry on Gut Microbiota and Metabolic Syndrome N/A
Completed NCT04960878 - The Effect of Synbiotics on the Upper Respiratory Tract Infection N/A
Active, not recruiting NCT05607745 - Dietary Counseling Coupled With FMT in the Treatment of Obesity and NAFLD - the DIFTOB Study N/A
Recruiting NCT04120051 - The SIMBA Project - The Effect of a Prebiotic Supplement on Glucose Metabolism and Gut Microbiota in Obese Adults N/A
Not yet recruiting NCT05481866 - Targeting Gut Microbiota and Metabolites for Very Preterm Infants Through Oropharyngeal Administration of Colostrum N/A
Completed NCT03293693 - Intake of Beta-glucan and Postprandial Regulation of Blood Glucose Metabolism in Healthy Subjects N/A
Completed NCT02207140 - Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly Phase 0
Recruiting NCT04203459 - The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota Regulation
Active, not recruiting NCT03259685 - Effect of Non-nutritive Sweeteners of High Sugar Sweetened Beverages on Metabolic Health and Gut Microbiome N/A
Recruiting NCT06157346 - Characteristics of Intestinal Bacteria and Their Effects on Growth and Immune Function in Children at High Altitude
Completed NCT03203044 - Impact of Soylent Consumption on Human Microbiome Composition N/A
Recruiting NCT05975541 - Susceptibility to Infectious Diseases in Obesity
Active, not recruiting NCT05457439 - Sustainable-psycho-nutritional Intervention Program and Its Effects on Health Outcomes and the Environment N/A
Recruiting NCT05065515 - Establishment of Individualized Immunotherapy Strategy and Platform Based on Changes of Intestinal Microbiota